Nicotine lozenges, tobacco-free snuff help smokeless tobacco users quit, study finds

Smokeless tobacco users who said they didn't want to quit changed their minds or significantly cut back when given nicotine lozenges or tobacco-free snuff in a Mayo Clinic study. The findings are published in the February issue of Addictive Behaviors.

Mayo researchers recruited 81 users of chewing tobacco or snuff with no intention of quitting in the next 30 days. Forty were given 4-mg nicotine lozenges and 41 received tobacco-free snuff to help cut back their use. They were asked to cut back 50 percent by one month and 75 percent by two months.

Participants received eight weeks of treatment and behavioral counseling on tobacco reduction strategies with follow-up to 26 weeks. Both groups significantly reduced smokeless tobacco use in cans used per week and dips per day and sustained it through the end of the study. About one-third of study participants continued using 75 percent less smokeless tobacco use 26 weeks after the study, and 12 percent of the participants quit using it completely.

"The reason why that is so striking and important to us is these patients had no intention of quitting," says addiction expert Jon Ebbert, M.D., a tobacco researcher at the Mayo Clinic Nicotine Dependence Center. "Through the process of just reducing their tobacco, participants wanted to quit and were successful in doing so."

Long-term smokeless tobacco use is associated with and cancer. Previous studies have evaluated the effectiveness of lozenges and tobacco-free snuff for reducing smokeless tobacco use among smokeless tobacco users not ready to quit, but no comparative effectiveness trials of these two products have been conducted, Dr. Ebbert says.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Researchers develop new tool to prevent heroin deaths

Aug 07, 2014

A new, lifesaving product aimed at reducing the death toll from heroin abuse—developed by a professor at the University of Kentucky College of Pharmacy—is in its final round of clinical trials and has received Fast Track ...

User comments